Drugs / Ceftazidim
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02463747 | Jun 2015 → Jun 2017 | neutropenia | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT02088970 Background | Sep 2014 → Apr 2017 | fungal keratitis | Nantes University Hospital | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ceftazidim | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02463747 ↗ |
| Known as | Fortum | “* Vancomycin + Fortum” NCT02088970 ↗ |
| Route | Intravenous | “Ceftazidim): 2.0gr, TID, I.V.” NCT02463747 ↗ |